Suven Life Sciences announces five poster presentations at SLEEP 2020 virtual conference
Hyderabad: Suven Life Sciences has announced that five posters on SUVN-G3031, a histamine-3 receptor inverse agonist will be presented at the upcoming 34thAnnual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2020." The meeting will be held virtually from August 27-30, 2020.
The poster presentations include a Phase-2 proof-of-concept study design that is currently recruiting the patients with narcolepsy with and without cataplexy, pharmacokinetic profile and safety findings from Phase-1 study, preclinical efficacy and differentiating features over current treatments of narcolepsy.
Details of the poster presentations are as below:
• Phase-2 proof of concept study of SUVN-G3031, a histamine H3 receptor inverse aagonist for the potential treatment of narcolepsy (Poster 0759)
• SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist: Safety, tolerability and pharmacokinetics following single and multiple ascending doses in healthy adult subjects (Poster 0760)
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.